• Explore /
  • Poster
  • / Oral paclitaxel and dostarlimab with or without trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant ISPY 2 TRIAL.

Oral paclitaxel and dostarlimab with or without trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant ISPY 2 TRIAL.

Abstract Poster

Authors

null

Rebecca Arielle Shatsky

University of California San Diego Medical Center, La Jolla, CA

Rebecca Arielle Shatsky , Alexandra Thomas , Christina Yau , Amy Jo Chien , Carla Isadora Falkson , Erica Michelle Stringer-Reasor , Coral Oghenerukevwe Omene , Meghna S. Trivedi , Judy Caroline Boughey , Amy Sanford , Mili Arora , Tara B. Sanft , Rita Nanda , Claudine Isaacs , Thelma Brown , Nola Hylton , Angela DeMichele , Douglas Yee , Laura Esserman

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Local/Regional/Adjuvant

Track

Breast Cancer

Sub Track

Neoadjuvant Therapy

Clinical Trial Registration Number

NCT01042379

Citation

J Clin Oncol 41, 2023 (suppl 17; abstr LBA612)

DOI

10.1200/JCO.2023.41.17_suppl.LBA612

Abstract #

LBA612

Poster Bd #

442

Abstract Disclosures

Similar Posters

First Author: Kay T Yeung

First Author: M. Luque

First Author: Alexandra Thomas

First Author: Sandra M. Swain